Gastric cancer is the leading cause of cancer death in China. Most patients are unresectable
or metastatic disease at the time of diagnosis. Systemic therapy was required for the
patients with advanced stage. Platinum combined with fluoropyrimidines always were considered
as first line treatment. After failure of initial therapy, single agent of taxanes was used
as second line treatment. However, there is no relative standard chemotherapeutic regimen in
the third therapy except oral anti-angiogenesis drug-Apatinib. So this study was designed to
explore the role of single agent with irinotecan as third line treatment in patients with
metastatic gastric cancer in China.